NCT06546007Recruiting
Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 6 Aug 2024
- Start date
- 13 Nov 2024
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Rarecells Diagnostics SAS
- Diseases
- Lung cancer
- NCT number
- NCT06546007
What you commit to
- Study type: Observational
- Planned participants: 50
- From 13 Nov 2024 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
- Patient treated with neoadjuvant treatment
Other illness
- Patient presenting psychiatric or neurological disorders preventing them from understanding the research
Other
- Pregnant women
Who the study is looking for
- Male or female aged between 35 and 85 years
- Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
- Patient capable of giving free, informed, and express consent
- The assessment of successful elected surgery implies, but is not limited to, the following:
- Exclusion of detectable extra thoracic and distant metastases
- Determination of the presence or absence of superior mediastinal lymph node metastases
- Definition of the histologic or cell type, whenever possible
- Evaluation of operative risk
Age in the registry: 35 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Università Cattolica del Sacro Cuore Gemelli Hospital Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.